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INTRODUCTION: Contrast-enhanced MRI (CE-MRI)
represents the current mainstay for monitoring treat-
ment response in glioblastoma multiforme (GBM),
based on the premise that enlarging lesions reflect in-
creasing tumor burden, treatment failure, and poor
prognosis. Unfortunately, irradiating such tumors can
induce changes in CE-MRI that mimic tumor recur-
rence, so called post treatment radiation effect (PTRE),
and in fact, both PTRE and tumor re-growth can
occur together. Because PTRE represents treatment
success, the relative histologic fraction of tumor
growth versus PTRE affects survival. Studies suggest
that Perfusion MRI (pMRI)–based measures of relative
cerebral blood volume (rCBV) can noninvasively esti-
mate histologic tumor fraction to predict clinical
outcome. There are several proposed pMRI-based ana-
lytic methods, although none have been correlated
with overall survival (OS). This study compares how
well histologic tumor fraction and OS correlate with
several pMRI-based metrics. METHODS: We recruited
previously treated patients with GBM undergoing surgi-
cal re-resection for suspected tumor recurrence and cal-
culated preoperative pMRI-based metrics within CE-
MRI enhancing lesions: rCBV mean, mode, maximum,
width, and a new thresholding metric called pMRI–frac-
tional tumor burden (pMRI-FTB). We correlated all
pMRI-based metrics with histologic tumor fraction
and OS. RESULTS: Among 25 recurrent patients with
GBM, histologic tumor fraction correlated most strong-
ly with pMRI-FTB (r5 0.82; P < .0001), which was the
only imaging metric that correlated with OS (P<.02).
CONCLUSION: The pMRI-FTB metric reliably esti-
mates histologic tumor fraction (i.e., tumor burden)
and correlates with OS in the context of recurrent
GBM. This technique may offer a promising biomarker
of tumor progression and clinical outcome for future
clinical trials.
Keywords: glioblastoma, histologic tumor fraction,
perfusion MRI, pseudoprogression, radiation necrosis,
recurrent, relative cerebral blood volume, survival.
A
s drug discovery programs search for new treat-
ment strategies to improve the survival of patients
with glioblastoma multiforme (GBM), the need
for a timely and accurate end point to judge treatment
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efficacy has never been greater.1 Overall survival (OS)
represents the benchmark measure of outcome but has
clear disadvantages for clinical trial assessment.
Clinical trials that use OS are lengthened because of
the time needed to observe mortality,1,2 and correlations
between OS and initial treatment are modified by subse-
quent salvage therapies.2,3 These limitations have led to
the use of progression-free survival (PFS) as a surrogate
marker for OS. However, PFS requires accurate esti-
mates of tumor growth based on MRI, and such esti-
mates are not always readily made, nor does PFS
correlate well with OS.2,3
Contrast-enhanced MRI (CE-MRI) represents the best
available method for measuring treatment response and
predicting survival after standard first-line therapy and is
used to define PFS.2–4Currently, decisions about treatment
are guided by criteria (Macdonald, RANO) that equate in-
creasing size of CE-MRI enhancement with progressive
tumor burden, treatment failure, and poor prognosis.5,6
Despite itswidespreaduse, thisapproachhasdistinct limita-
tions. First,CE-MRI cannot distinguish tumorgrowth from
treatment-induced parenchymal injury, so called post-
treatment radiation effect (PTRE), which exactly mimics
tumor on CE-MRI. Two well documented forms of PTRE
are pseudoprogression (pP) and radiation necrosis (RN).
Unlike tumor, PTRE represents a positive response to treat-
ment and, therefore, a good prognosis; however,
PTRE-related enhancement underlies erroneous declar-
ation of treatment failure in up to half of cases.7–10
In addition, tumor often coexists and variably admixes
with PTRE in most patients.11 The histologic tumor frac-
tion (i.e., tumor burden) therefore comprises a subcompo-
nent of the total CE-MRI enhancement and represents a
potentially useful predictor of survival in patients with re-
current brain tumor.12–14 In fact, studies suggest that his-
tologically quantifying tumor burden provides more
meaningful prognostic information than simply reporting
the presence of tumor.12–15 Because CE-MRI cannot reli-
ably distinguish the coexistence of PTRE and tumor
burden, surgical biopsy and histologic evaluation remain
the current benchmark.13 Unfortunately, surgery is not
without medical risk, morbidity, and cost. These issues
underscore a clear need to develop a noninvasive
method to accurately estimate tumor burden as a potential
alternative or adjunct to surgical biopsy.
PerfusionMRI (pMRI) noninvasively detects GBM and
PTRE microvascular characteristics, most commonly
with the dynamic susceptibility-weighted contrast-
enhanced (DSC) method. With use of pMRI, relative cere-
bral blood volume (rCBV) is measured on a voxel-wise
basis across CE-MRI lesions, providing regionally specific
estimates of tissue microvasculature and histologic iden-
tity.16–24 To date, several pMRI-based analytic methods
have been proposed to estimate histologic tumor fraction,
eachwithpotential advantages and limitations. First, calcu-
lating mean rCBV across all CE-MRI lesion voxels is the
easiest method but does not assess intervoxel variations
thatmay reflect histologic heterogeneity.16,17 Second, histo-
gram analysis contributes additional metrics, including
mode, maximum, and histogram width, although these
may be biased by spatial statistics.18,19 Finally, the voxel-
based thresholding method applies predetermined rCBV
criteria to classify individual voxels based on histologic
identity, but requires that the accuracy of the threshold be
prospectively validated.20,21
To date, no published studies support consensus
regarding which pMRI-based analytic method best esti-
mates histologic tumor fraction as a predictor of survival
in recurrent GBM. Our hypothesis is that tumor burden
and OS will correlate more strongly with those
pMRI-based methods that use a voxel-based approach
to assess histologic heterogeneity. We here report a
study in a cohort of patients with recurrent GBM with
CE-MRI evidence of tumor progression. Our goals
were to (1) determine the strengths of correlation
between histologic tumor fraction and previously pub-
lished pMRI-based metrics (rCBV mean, mode,
maximum, and histogram width) and a new voxel-based
thresholding metric, called pMRI fractional tumor
burden (pMRI-FTB), and (2) identify which
pMRI-based metric best correlates with OS.
Methods
Patients
We recruited patients with recurrent GBM undergoing
image-guided stereotactic surgical re-resection of newly
developed or enlarging lesions identified on surveillance
CE-MRI. Prior to enrollment, all study patients had
undergone surgery and received temozolomide (TMZ)
and radiation therapy (RT) according to the Stupp
protocol.4 We documented the timing of CE-MRI
lesion development relative to prior treatment, excluded
subjects with estimated glomerular filtration rate (eGFR)
,60 mg/min/1.72m2, and obtained approval from the
Institutional Review Board and written informed
consent from each subject. The histopathology and
MRI data were obtained and recorded independently
of each other before correlation was determined.
Preoperative DSC-MRI Protocol
We used a 3 Tesla MR system (General Electric Medical
Systems) for all patients. After antecubital fossa or
forearm intravenous catheter placement and 6 minutes
prior to the DSC-MRI acquisition, we administered
0.1 mmol/kg Gd-DTPA contrast agent (gadodiamide
or gadobenate dimeglumine) preload dose to minimize
T1W leakage effects.22–25 During acquisition, we gave
0.05 mmol/kg bolus at 3–5 cc/sec.22–25 The
DSC-MRI sequence parameters were: Gradient-echo
Echo Planar Imaging (EPI) with TR (msec)/TE (msec)/
flip angle ¼ 1500–2000/20/60o; FOV 24 × 24 cm,
matrix 128 × 128, 5 mm slice; no interslice gap. These
parameters yielded an in-plane spatial resolution of
1.8 × 1.8 mm and voxel volumes of 0.02 cm3. The
total Gd-DTPA dose was 0.15 mmol/kg body weight.
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Preoperative Stereotactic Anatomical Data Set
We obtained pre- and postcontrast T1W Spoiled
Gradient-Echo (SPGR-IR prepped) stereotactic MRI
data sets (TI/TR/TE ¼ 300/6.8/2.8 msec; matrix
320 × 224; FOV ¼ 26 cm; slice thickness ¼ 2 mm)
before and after DSC-MRI for neuronavigation during
surgical resection. We performed all imaging within
one day of surgery. We used IB Suite (v. 1.0.454)
(Imaging Biometrics) to coregister the stereotactic ana-
tomical images with the DSC-MRI data and rCBV
maps, using multiple registration methods implemented
in ITK, the Insight Segmentation and Registration
Toolkit (www.itk.org), similar to previously described
methods.19,20,22,23
Relative Cerebral Blood Volume (rCBV) and rCBVMap
Generation
We used an Osirix (v. 3.6.1) workstation with IB Neuro
(v. 1.1.430) and IB Suite (v. 1.0.454) (Imaging
Biometrics) software to calculate whole-brain rCBV
maps from the DSC data, coregistered to stereotactic
data. RCBV was calculated based on well-established
methods.22–24 In short, after excluding the first 4 time
points of each DSC-MRI series due to saturation
effects, we normalized signal intensity (SI) to baseline
and converted series to change in relaxivity over time
[DR2*(t)] for the entire brain. We generated CBV
maps by integrating the area under the DR2*(t) curve,
ending at the time point forty seconds after the nadir
SI of the first pass-bolus. All CBV values were corrected
for T1W leakage with preload dosing, and a modeling
algorithm was used to correct T2/T2*W residual
effects.23 CBV maps were normalized to contralateral
normal appearing white matter (NAWM) to create
rCBV maps.22–24
Acquisition of Surgical Tissue, Criteria for Histologic
Diagnosis, and Estimation of Histologic Tumor Fraction
For all patients, we collected surgical tissue intraopera-
tively frommultiple stereotactic biopsies and surgical re-
section, and we used only tissue collected from
contrast-enhancing portions of the CE-MRI lesions for
the purposes of this study. We fixed all surgical tissue
specimens in 10% formalin, embedded in paraffin,
sectioned (10-micron), and H&E stained per standard
diagnostic protocol at our institution. Two neuropathol-
ogists recorded the presence and quantity of GBM and/
or PTRE elements for all specimens without knowledge
of DSC-MRI results.11,12,26 In short, for all submitted
surgical tissue, 2 neuropathologists simultaneously
estimated the histological fractional volume of tumor
relative to nonneoplastic features, based on relative
fractions of treatment effects versus neoplastic features,
as previously described.12–15,18,20 Both neuropatholo-
gists reached a concordance on the majority of cases
reviewed. The rare case for which there was disagree-
ment was re-reviewed and a concordant diagnosis was
reached. Some cases had multiple slides available for
review. These cases were noted to be difficult to evaluate
because of the numbers of slides. Areas of tumor and
PTRE were marked on each slide, grossly measured,
microscopically re-evaluated, and a concordance
reached on percentage of tumor/PTRE.
PTRE features included pauci-cellularity, scattered
rare or no atypical cells, lack of mitotic figures except
in inflammatory cells, preponderance of reactive cells in-
cluding astrocytes (gemistocytes), microglia and macro-
phages, and vascular hyaline fibrosis. Necrosis, often
circumscribed in nonneoplastic parenchyma, if present,
was considered to be specific for PTRE. Features of
tumor recurrence included cellular sheets and/or nests
of atypical cells often with mitotic figures. If necrosis
was present, it was a minor component of the cellular
tumor rather than parenchyma. The finding of fewer
atypical cells, in a linear infiltrative configuration in par-
enchyma without prominent reactive changes, was also
classified as recurrence.
Classifying Stereotactic Tissue Specimens and
Determining an Optimal rCBV Threshold to
Distinguish GBM and PTRE
In an initial subset of 26 stereotactic biopsy samples
from the first 9 patients with GBM in our series, we
recorded the biopsy locations during neuronavigational
surgery21 and categorized all biopsy specimens as
either tumor or PTRE on the basis of the aforementioned
histologic criteria. Consistent with prior convention,
samples containing a mixture of both GBM and PTRE
were classified as tumor, regardless of the degree of ad-
mixture.12,21,27 Only samples with pure radiation
change (in the absence of tumor criteria) were categor-
ized as PTRE. The presence of a few isolated, scattered
atypical cells did not qualify as tumor categorization if
other neoplastic features were absent. For each biopsy
sample, we placed a coregistered 3 × 3 voxel
(0.3 cm2) region of interest (ROI) centrally within cor-
responding recorded stereotactic locations, yielding a
localized mean rCBV that was correlated with the
categorization of tumor or PTRE. We evaluated each
rCBV value as a potential threshold value to distinguish
PTRE and tumor across all 26 biopsy samples. At each
rCBV cutoff, we determined the sensitivity, specificity,
95% confidence intervals (CI), and accuracy (defined
as the average of sensitivity and specificity) for distin-
guishing PTRE and tumor. We defined the optimal
threshold rCBV as the value that yielded the highest
accuracy, and we used this threshold for all subse-
quent analyses to classify individual voxels as tumor or
PTRE.
Correlating Intervoxel rCBV Variability and Histologic
Heterogeneity for Stereotactic Biopsy Samples
Containing Tumor
Previous studies using the binary classification of tissue
samples as tumor and PTRE reported broad variability
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in the degree of histologic admixture within the tumor
category.13–16,18,20 We used the initial set of 26 biopsy
samples (from 9 patients) to test whether the voxel-
based application of our optimized threshold could esti-
mate tumor/PTRE admixture within the biopsy samples
containing tumor. To accomplish this, we studied the
intervoxel rCBV variability within each 3 × 3 voxel-
sized ROI corresponding to the biopsy samples that
were categorized as tumor. For each ROI, we calculated
the percentage of voxels with rCBV above threshold
(determined in the previous section) that were predictive
of tumor. We used Pearson correlation to compare this
percentage with the histologic tumor fraction from
each biopsy (using the histologic criteria described
above) (P, .05). Similarly, we correlated the rCBV
mean (of all 9 voxels) for each ROI with the histologic
tumor fraction from corresponding biopsy samples that
were categorized as tumor.
Fig. 1. Flow Diagram for Calculation of Perfusion MRI-Fractional Tumor Burden (pMRI-FTB). The pMRI-FTB metric is calculated for CE-MRI
enhancing lesions using the following algorithm: (A) we subtracted pairs of voxel values between coregistered precontrast (left) and
postcontrast (middle) anatomical images to identify enhancing tissue (right); (B) we establish a Volume of Interest (VOI) (left, green line)
by manually tracing the periphery of enhancing lesions, excluding visible surrounding vascular structures. Based on signal intensity ranges
within the VOI (right), a lesion mask is created that includes enhancing voxels (white) and excludes nonenhancing and necrotic voxels
(black); 3) Following coregistration with the rCBV map, the lesion mask voxels are categorized as tumor (red) or PTRE (white) based on
the optimized rCBV threshold (shown in Fig. 1C). We defined pMRI-FTB as the percentage of tumor voxels relative to total lesion mask
voxels.
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pMRI-FTB
For all patients in this study (including the initial set of 9
patients), we calculated pMRI-FTBwithin entire CE-MRI
enhancing lesions using the following algorithm (summar-
ized in Fig. 1): we subtracted pairs of voxel values
between coregistered pre- and postcontrast anatomical
images to identify enhancing tissue; we established a
volume of interest (VOI) by manually tracing the periph-
ery of enhancing lesions, excluding visible surrounding
vascular structures. Based on signal intensity ranges
within the VOI, a lesion mask was created to include en-
hancing voxels and exclude nonenhancing and necrotic
voxels. After coregistration with rCBV maps, the lesion
mask voxels were categorized as tumor or PTRE based
on the optimized rCBV threshold (determined in the
section above). We defined pMRI-FTB as the percentage
of tumor voxels relative to total lesion mask voxels.20
We excluded any visible regions of decreased signal on
EPI native images prior to contrast bolus arrival suggest-
ive of blood products or susceptibility artifact typically
observed at the skull base due to air-brain interfaces.21
Mean rCBV and Other rCBV Histogram Metrics
For all patients in this study (including the initial set of 9
patients), we analyzed all voxels within enhancing lesion
masks as defined in the pMRI-FTB section above to
calculate other rCBV metrics based on histogram
analysis.16,18,19 We calculated mean rCBV as the
average of all rCBV values from the lesion mask
voxels16,17 and generated histograms based on previous-
ly published methods.18,19 In short, histograms were first
generated by classifying all lesion mask rCBV values into
a predefined number of bins. We divided the interval
between the minimum and maximum voxel values into
108 equally spaced bins, counted the number of voxels
within each bin, and plotted frequency as a function of
bin number. We kept the range of rCBV values along ab-
scissa constant (0–10) to calculate the following nor-
malized histogram metrics: mode (rCBV with greatest
frequency), maximum (greatest rCBV value), and histo-
gram width (difference between maximum and
minimum rCBV values).18
Statistical Analyses
Figure 2 provides a flow chart summarizing the major
statistical analyses between the initial (training) set, the
validation set, and the entire cohort. We calculated
Pearson correlations between histologic tumor fraction
and all pMRI-based metrics for all patients. We used
the date of surgical re-resection to determine overall
Fig. 2. Flow chart depicting the data collection and analyses for initial (training) and validation data sets, as well as the entire patient cohort.
The initial (training) set was composed of 26 stereotactic biopsy samples from 9 subjects. Image coregistration enabled direct correlation
between regions of interest (ROIs) on imaging and tissue analyses from corresponding biopsies. The validation data set was composed
of 16 additional subjects but did not include stereotactic analysis. The total data set included patients from the initial and validation
groups, and was composed of all 25 subjects. The (*) denotes the analysis that determined the most accurate rCBV threshold
to distinguish biopsy specimens containing pure PTRE from those containing tumor. The (††) denotes that Pearson correlation was used
to compare stereotactic biopsy results with coregistered, localized ROI analyses. The (||) denotes that Pearson correlation was used to
compare pMRI metrics from an entire CE-MRI enhancing lesion with histologic analyses from all submitted surgical resection tissue. The
(}) denotes that Cox-regression analyses were used to compare Overall Survival (OS) with all pMRI-based metrics from an entire
CE-MRI enhancing lesion, as well as histologic analyses from all submitted surgical resection tissue.
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survival (OS) and correlated OS with pMRI-based
metrics using Cox regression. We assessed whether
extent of surgical resection (i.e., total versus subtotal re-
section) was associated with OS via Cox regression ana-
lysis. We consider Cox regression to be the primary
analysis method for determining correlations with
outcome, because the metrics are treated as continuous
variables without the use of predetermined categories
or cutoff values. However, as a secondary method for
determining correlations with outcome, we also used
Log-rank tests to compare OS with histologic tumor
fraction and all pMRI-based metrics. For each of these
secondary analyses, we stratified patients into 2 categor-
ies (high or low) using the respective image-based or
histologic-based group median values as cutoffs, with
high categories having values above our patients’
median and low categories having values equal to/less
than the overall median. A biostatistician (AD) per-
formed all analyses; statistical significance was indicated
by P, .05.
RESULTS
Subject Population and Clinical Data
Twenty-five patients (18 males, 7 females) with recur-
rent GBM were recruited into the study, with a median
age of 50 years (range, 25–73 years). Sixty-four
percent of patients (16/25) developed progressively en-
larging CE-MRI enhancing lesions within 6 months of
initial TMZ-RT (range, 1.0–5.5 months; median, 4
months), whereas 36% (9/25) developed lesions more
than 6 months post TMZ-RT (range, 8–53 months;
median, 12 months). All patients underwent either
total (n ¼ 11) or subtotal (n ¼ 14) resection of their
posttherapy enhancing lesions. OS was not associated
with extent of re-resection (P ¼ .79), size of the
enhancing CE-MRI lesion (P ¼ .56), or patient age
(P ¼ 0.26). One of the 25 patients received prior bevaci-
zumab for recurrent disease but failed this therapy, as
evidenced by progressive increasing enhancement and
mass effect on serial CE-MRI examinations prior to en-
rollment. We performed analyses both with and without
inclusion of this patient; the pMRI correlations with
histology and OS remained consistent under all condi-
tions, thereby justifying this patient’s inclusion. We
report results for the complete cohort of 25 patients.
Optimal rCBV Threshold to Classify GBM and PTRE
Voxels
Figure 3 shows that a threshold of 1.0 categorized
stereotactic biopsy specimens as either tumor (.1.0)
(n ¼ 17) or PTRE (≤1.0) (n ¼ 9) with 100%
accuracy (sensitivity¼ 100%, 95%CI¼ 80.5–100%;
specificity¼ 100%, 95%CI ¼ 66.4–100%) based on
the initial set of 26 stereotactic biopsies (from 9 subjects)
and corresponding rCBV values. This threshold was used
for all subsequent pMRI-FTB analyses to classify individ-
ual voxels as either tumor or PTRE.
Correlating Intervoxel rCBV Variability and Histologic
Heterogeneity for Stereotactic Biopsy Samples
Containing Tumor
The rationale for using stereotactic coregistration to
compare localized pMRI measurements with the stereo-
tactic biopsies was to minimize the risk of sampling error
that might confound the correlation between imaging
and tissue analysis. Of the initial 26 biopsy specimens
(from 9 patients) described above, 9 biopsies contained
pure PTRE and 17 biopsies contained some degree of
tumor that varied in regards to histologic tumor fraction
(median ¼ 75%; range, 1%–100%). For all tumor
biopsies, the mean rCBV value from each ROI
was .1.0 threshold (group median ¼ 1.5; range ¼
1.02–5.72), although in some ROIs, there was variabil-
ity in the number of individual voxels that were .1.0.
Fig. 3. Optimal rCBV Threshold to classify GBM and PTRE voxels:
We established the relationship between rCBV and histopathologic
diagnosis from an intial subset of 26 stereotactic biopsy samples
through careful coregistration of pMRI ROIs and stereotactic
locations, using nine-voxel-sized ROIs (0.18 cm3) to approximate
tissue specimen volume (0.2 cm3). We averaged rCBV across
nine voxels to minimize coregistration error while enabling
separation of pure PTRE from tumor specimens with no rCBV
overlap. The threshold of 1.0 separated specimens categorized as
“tumor:” (n ¼ 17) or “PTRE” (n ¼ 9) with 100% accuracy
(sensitivity ¼ 100%, 95%CI ¼ 80.5–100%; specificity ¼ 100%,
95%CI¼ 66.4–100%). The PTRE values clustered tightly at and
below the rCBV threshold of 1.0, suggesting there was histologic
homogeneity across specimens. In contrast, rCBV in GBM varied
broadly above 1.0 suggesting variability in tumoral angiogenesis
and the degree of histologic admixture with PTRE.
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Specifically, some tumor biopsy ROIs demonstrated a
relatively higher percentage of voxels equal to or
below threshold (i.e., PTRE voxels), compared with
other samples with relatively more ROI voxels above
threshold (i.e., tumor voxels). For each ROI, we found
that the percentage of tumor voxels (median ¼ 89%;
range, 22%–100%) correlated with the histologic
tumor fraction from corresponding biopsy specimens
(n ¼ 17, r ¼ 0.72, P, .002).
To adjust for potential bias resulting from a differ-
ent number of tissue samples collected from each
subject, we performed a bootstrap analysis in which
Pearson correlations were computed with random se-
lection of one specimen per subject. For the compari-
son between percentage of tumor voxels and
histologic tumor fraction within each biopsy, the cor-
relation remained consistent with the original analysis
(average r ¼ 0.68, standard error ¼ 0.003). This sug-
gests that intrasubject grouping effects, if present,
did not significantly bias the correlations across the
entire group of specimens. The rCBV mean (of all 9
voxels) for each ROI correlated poorly with histologic
tumor fraction (n ¼ 17, r ¼ 0.36, P ¼ .17). Figure 4
shows an example of rCBV variability in correspond-
ing biopsy samples with high and low histologic tumor
fraction.
Correlations between pMRI-Based Metrics, Histologic
Tumor Fraction, and OS
For all 25 patients, we quantified histologic tumor frac-
tion from the combination of all submitted surgical re-
section material and stereotactic biopsies. Histologic
tumor fraction most strongly correlated with
pMRI-FTB (r ¼ 0.82, P, .0001), compared with other
pMRI-based metrics, as summarized in Table 1 and in
Fig. 5. The initial (training) subset of 26 biopsy
samples (from 9 subjects) was included in this analysis,
because the biopsies represented only a fraction of sub-
mitted surgical tissue from the respective patients.
Nonetheless, to test whether the correlation between
histologic tumor fraction and pMRI-FTB significantly
differed between the subjects in the initial training set
(n ¼ 9) versus those not in the training set (n ¼ 16), we
performed separate Pearson correlations for each of
these 2 groups (summarized in the footnote of
Table 1). Because these correlations for the 2 groups
were essentially identical (n ¼ 9, r ¼ 0.84, P, .01 and
n ¼ 16, r ¼ 0.82, P, .001, respectively), it was highly
unlikely that the correlation in the training set was dis-
proportionately driving that of the entire cohort.
Figure 6 shows an example of pMRI-FTB maps in 2
patients with different histologic tumor fractions from
Fig. 4. Two recurrent GBM stereotactic biopsies showing different histologic tumor fractions and rCBV measurements. (A) Coregistration of
pMRI-FTB and neuronavigational images enabled demarcation of voxels predictive of tumor (red), based on rCBV values above the threshold
of 1.0. (B,C) We measured rCBV at two biopsy locations (boxes with arrowheads) defined by nine-voxel Regions of Interest (ROIs). In
magnified views of the ROIs mean rCBV for both biopsies were above 1.0, corresponding to the presence of tumor within each sample.
(D,E) When analyzing individual voxels comprising each ROI, biopsy #2 (E) demonstrated greater intervoxel rCBV variability compared
with biopsy #1 (D), such that the percentage of voxels above threshold (red) was lower for biopsy #2 (E). The lower percentage of
tumor voxels on pMRI correlated with lower histologic tumor fraction within the biopsy sample (F,G). The data from Figs 3 and 4
suggest that rCBV thresholding can be applied, not only to multi-voxel ROIs, but also to single voxels to exclude the presence of tumor.
In this study, single-voxel thresholding depicts histologic tumor fraction more accurately than the mean rCBV from nine-voxel ROIs, by
identifying subregions of PTRE at nine-fold higher spatial resolution.
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surgical specimens. At the time of this analysis, 15 patients
haddied.Median clinical follow-up for livingpatientswas
455 days from the time of initial treatment and 151 days
from the time of surgical re-resection.OSwas significantly
associated with only histologic tumor fraction (P, .03)
and pMRI-FTB (P, .02), but not with mean rCBV or
any other histogram analysis metrics (Cox regression
analysis). Qualitatively, the distributions of the rCBV his-
tograms were generally unimodal and similar to previous
reports.18,19 Histogram width was nearly identical to
histogrammaximumvalue, asminimum values for all his-
tograms were close to zero. Table 1 summarizes the range
and group median values for histologic tumor fraction,
pMRI-based metrics, and their correlations with OS.
Secondary analyses using Log-rank test demonstrated sig-
nificantly shorter OS in patients with high pMRI-FTB
(above the group median of 63%, P, .03) or high histo-
logic tumor fraction (above the group median of 49%,
P, .04), compared with counterparts with low values.
Log-rank survival analyses were not significant for rCBV
Fig. 5. Pearson correlations between histologic tumor fraction and different pMRI-based metrics. The scatterplot graphs demonstrate that
histologic tumor fraction correlates most strongly with pMRI-FTB (A), compared with mean rCBV (B) and histogram mode rCBV (C). The r
correlation coefficients and p values are included in the respective graphs.
Table 1. Summary of correlations between pMRI-based metrics, histologic tumor fraction, and overall survival (OS)
Metric Median value (range) Correlation with Histologic Tumor Fraction
(P value)
P value for correlation with OS*
Histologic Tumor Fraction 49% (0–98) – ,0.03
pMRI-FTB 63% (16–99) r ¼ 0.82 ** (P, .0001) ,0.02
Mean rCBV 1.6 (0.6–4.7) r ¼ 0.57 (P, .01) Ns (0.45)
Histogram Mode (rCBV) 1.1 (0.06–4.5) r ¼ 0.62 (P, .001) Ns (0.17)
Histogram Width (rCBV) 9.9 (3.8–20.4) r ¼ 0.08 (P ¼ .69) Ns (0.28)
Histogram Max (rCBV) 9.9 (3.8–20.4) r ¼ 0.08 (P ¼ .69) Ns (0.28)
*Based on Cox-regression analysis.
*“Ns” denotes Nonsignificant survival correlation.
**The correlation listed in the table is for the entire cohort of 25 subjects. The correlation among subjects in the initial training set (n ¼ 9)
was r ¼ 0.84, P, 0.01; the correlation among subjects not in the training set (n ¼ 16) was r ¼ 0.82, P, .001.
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mean (P¼.37), mode (P ¼ .25), maximum (P ¼ .28), or
histogram width (P ¼ .28).
Discussion
This study correlated multiple, distinct pMRI-based
metrics with histologic tumor fraction and OS in a
cohort of patients with recurrent GBM undergoing sur-
gical re-resection for suspected tumor regrowth. Unlike
prior studies,16,18,20,27,28 we did not use predetermined
histologic tumor fraction categories, because we chose
not to assume prior knowledge of which histologic cri-
teria would be clinically relevant to OS. Instead, we dir-
ectly compared the imaging and histologic measures as
continuous variables to identify broad correlations
with OS and any potential pMRI-based predictors of
outcome for future validation studies. Overall,
pMRI-FTB provided the most robust estimate of histo-
logic tumor fraction and was the only imaging metric
that correlated with OS. Other pMRI-based metrics,
such as rCBV mean and mode, correlated less strongly
with histology and did not correlate with OS. Our find-
ings that pMRI-FTB and histologic tumor fraction both
correlate with OS suggest that both are good indicators
of tumor progression and clinical prognosis. We intend
to validate the correlation between pMRI-FTB and sur-
vival in future clinical trials.
There are few reports in the literature attempting to
correlate pMRI methodologies with histologic tumor
fraction and CE-MRI lesions in patients with recurrent
GBM. Virtually all studies view CE-MRI lesions as
either tumor or PTRE, although the vast majority of
lesions are in fact histologically admixed and broadly
variable in tumor fraction.18,27–29 Thus, the literature
proposes lesion categorization criteria that depend on
various histologic tumor fraction cutoff values. In
general, image-based studies have preserved these
cutoff values, but have not considered survival relation-
ships. This has resulted in variable histologic standards,
making unbiased comparison of pMRI-based metrics
difficult. For example, Barajas et al.16 studied mean
Fig. 6. Measures of pMRI-FTB and histologic tumor fraction from two patients with CE-MRI enhancing lesions suspicious for recurrent GBM.
(A,C) Color pMRI-FTB maps depict red voxels as those with rCBV above threshold that are predictive of tumor. The pMRI-FTB metric
represents the percentage of tumor voxels relative to total enhancing CE-MRI lesion voxels. In the first patient, pMRI-FTB of 99%
(A) correlated with high histologic tumor fraction of 85% (B). In contrast, the second patient demonstrated low pMRI-FTB (C) and low
histologic tumor fraction (D). These cases illustrate the utility of pMRI-FTB to noninvasively estimate tumor burden as a fractional
subcomponent of otherwise nonspecific CE-MRI lesions.
Hu et al.: Perfusion MRI quantifies recurrent GBM tumor fraction
NEURO-ONCOLOGY † J U L Y 2 0 1 2 927
rCBV and chose a 5% cutoff to classify CE-MRI lesions
as tumor, whereas Gasperetto et al.20 studied rCBV
thresholding and chose a 20% cutoff. Kim et al.18
studied various histogram-based metrics, but chose to
separate CE-MRI lesions into three histologic categories,
based on the histologic tumor fraction ranges of ,20%,
20–50%, and .50%. Because these studies did not cor-
relate results with survival, their underlying clinical jus-
tification may be limited.
Prior histology-based studies suggest that cutoff
values guiding lesion classification can impact the rela-
tionship between tumor fraction and survival.12–15
Tihan et al. evaluated a 25% cutoff in a cohort of
patients with recurrent GBM and reported no survival
difference between radionecrosis and tumor groups.15
Forsyth et al. reported significant group survival differ-
ences using a 75% cutoff, although the cohort consisted
of mixed tumor grades (II-IV).12 Kim et al. recently
reported survival differences within a cohort of 20
patients with recurrent GBM, using 3 histlologic cat-
egories based on the cutoff values of ,20% and
.80% recurrent tumor fraction.14 Because these
studies, to our knowledge, comprise the world literature
correlating histologic tumor fraction with prognosis,
further investigation is warranted, particularly in recur-
rent GBM cohorts. The Cox regression analysis from our
pilot study suggests that histologic tumor fraction (like
pMRI-FTB) correlates directly with survival, irrespective
of classification methods and predetermined cutoff
values. As further proof of concept, our secondary ana-
lyses using Log-rank tests suggest that the histologic
cutoff of 50% was predictive of survival in our cohort;
however, we are wary to recommend the prospective
use of any particular cutoff value, until these data can
be validated in a larger GBM population.
The relationships between rCBV, histologic tumor
fraction, and clinical outcome warrant further discus-
sion. In this study, we specifically evaluated the utility
of rCBV (as analyzed by various methods) to estimate
histologic tumor fraction as a predictor of outcome.
Compared to the pMRI-FTB metric, the magnitude of
mean rCBV showed weaker correlation with histologic
tumor fraction. This is because mean rCBV (similar to
other histogram-based metrics) is influenced by the mag-
nitude of rCBV from both tumoral and nontumoral
(PTRE) components. In addition, GBM exhibits micro-
vascular heterogeneity and broad rCBV variability
even among tumor subregions,30–33 and the calculation
of mean rCBV is susceptible to biases from extremely
high or low values, even in a relatively small population
of voxels. In contrast, rCBV magnitude has less impact
on the calculation of pMRI-FTB, except to classify
voxels according to minimum threshold requirements.
This approach more purely approximates the volume
of tumor burden by mitigating influences from varying
degrees of tumoral angiogenesis. As an example, a
voxel with rCBV of 1.2 will be classified as tumor in
the same manner as another voxel with rCBV of 12.0.
We must also address the fact that tumoral angiogen-
esis and rCBV magnitude are well-established, inde-
pendent prognostic markers in newly diagnosed and
recurrent glioma.33–35 In a previous study that used
stereotactic analysis to correlate rCBV with tumor
micro-vasculature, both rCBV magnitude and microves-
sel area predicted OS in a cohort of patients with recur-
rent high-grade glioma.33 However, our current study
did not show a correlation between rCBV magnitude
(i.e., mean) and OS. A plausible explanation is that the
previous study excluded regions of PTRE from rCBV
and histologic analyses. Unlike our current study, their
mean rCBV calculations did not include potentially con-
founding contributions from PTRE components, which
may have helped to retain the prognostic value of
rCBV magnitude within tumor. Further studies are
likely warranted to distinguish histologic tumor fraction
and degree of angiogenesis as separate and independent
prognostic indicators in recurrent GBM. Besides measur-
ing rCBV at a single time, other groups have also shown
the prognostic value of assessing the magnitude of
change in rCBV before and after treatment.34,35
In the current study, we used careful stereotactic cor-
egistration to establish the rCBV threshold of 1.0 that
differentiates PTRE and tumor specimens with 100%
accuracy. The current rCBV threshold is slightly higher
than the one that we previously reported.21 In the
current study, we optimized several postprocessing
steps to increase the clinical robustness and reproducibil-
ity of pMRI analysis across institutions, and to help
streamline clinical workflow. We also chose to normal-
ize CBV only to normal appearing white matter
(NAWM). This method differs from prior use of both
gray matter (GM) and NAWM for normalization,21
but has been shown to provide greater rCBV measure-
ment stability under varied pMRI acquisition condi-
tions.24 Because GM has higher microvascular volume,
compared with NAWM, the rCBV values will be inher-
ently lower when normalizing against GM, as opposed
to NAWM.24 In addition, we used a commercially avail-
able software package that corrected T2/T2*W residual
effects with a modeling algorithm, compared with prior
use of baseline-subtraction (BLS). Modeling correction,
compared with BLS, does not require manual user
input to define the first pass interval of the contrast
bolus, thereby reducing operator-dependent variability
and overall postprocessing time.21,23,24 It is also possible
that these methodological differences may have contrib-
uted to the differences in rCBV threshold.22–24 Of note,
although the thresholds varied slightly between studies,
the accuracy to distinguish GBM from PTRE remained
consistently high. We feel that the current methods
described here, using the rCBV threshold of 1.0, enable
robust calculation of pMRI-FTB on a clinical basis and
across multiple institutions.
Since the adoption of combined TMZ and RT as
standard adjuvant treatment for GBM, there has been
increasing awareness of therapy-related parenchymal
injury, so called PTRE, which mimics tumor regrowth
on CE-MRI. PTRE results from treatment-induced
tumor and endothelial-cell death that causes vasogenic
edema and enhancement on CE-MRI.7–10 Both pP and
RN are widely described forms of PTRE that mimic
tumor regrowth but differ in timing and severity. The
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mild and self-limited pP develops within 3–6 months of
RT, often before adjuvant TMZ is completed. Thus, er-
roneous interpretation of pP as treatment failure can
lead to premature cessation of chemotherapy.8,9,13 In
contrast, RN develops .6 months after RT and is
more severe, typically requiring steroids or surgical
debulking. The development of pP markedly increases
the risk for subsequent RN, supporting shared patho-
physiology between the 2 entities.8,9,13 In our cohort,
the vast majority of lesions contained histologic admix-
ture between tumor and PTRE, with most lesions devel-
oping during the time frame of pP.
The reliance on conventional imaging to distinguish
tumor from PTRE leads to diagnostic inaccuracy and po-
tential clinical inefficiency. For instance, the proposed
workaround to the poor accuracy of CE-MRI is to use
serial changes in lesion size over multiple CE-MRI exam-
inations to distinguish pP from tumor, based on the
premise that lesions decreasing in size likely represent
pP;6–9 however, histologic admixture in the vast major-
ity of lesions often degrades the accuracy of this ap-
proach. Specifically, the pP subcomponents within an
admixed lesion may decrease in size over time,
whereas the tumoral subcomponents may increase. In
addition, it is not uncommon for PTRE or indolent
tumor to remain stable over time. Thus, the overall
size of a CE-MRI lesion is the sum of dynamic changes
from multiple competing histologic processes that
makes it difficult to accurately judge tumor burden. In
addition, serial imaging requires months to reach a diag-
nosis, during which time tumor progression may have
occurred. Consequent delay in appropriate therapy
may ultimately reduce treatment efficacy or increase tox-
icity, because the tumor invades surrounding brain par-
enchyma. Compared with serial CE-MRI examinations,
pMRI-FTB can estimate tumor burden in an accurate
and timely manner during a single examination. This
may provide a useful imaging endpoint for defining
PFS and predicting OS in future clinical trials.1–3
We recognize several potential limitations to this
study. Despite high correlation between pMRI-FTB and
histologic tumor fraction, pMRI-FTB was consistently
higher than the histologic tumor fraction. This might be
explained by resolution differences between pMRI (milli-
meters) and histology (microns). In addition, it is possible
that sampling errors resulted in consistent underestima-
tion of tumor burden on histology; these errors would
not affect pMRI-FTB, which can assess CE-MRI lesions
in their entirety. The patient sample size was small, and
these results should be validated in a larger GBM popula-
tion. There could have been small misregistration errors
between localized pMRI ROI placement and the stereo-
tactic biopsy locations, caused by errors in coregistration,
image distortions and brain shift following craniotomy.
To compensate, neurosurgeons used small craniotomy
sizes to minimize brain shift and also visually validated
stereotactic image location with intracranial neuroana-
tomical landmarks to help correct for random brain
shifts. Rigid-body coregistration of stereotactic and
DSC-MRI also helped reduce possible geometric distor-
tions. Thus, the misregistration in this study was likely
no greater than 1–2 mm and similar to that of previous
studies using stereotactic biopsy.21,27,28,32
Conclusion
pMRI-FTB can reliably estimate histologic tumor frac-
tion within otherwise nonspecific CE-MRI enhancing
lesions. Our study shows that quantifying tumor
burden, relative to components of pseudoprogression
and radiation necrosis, can help to predict survival in
the setting of recurrent GBM. This suggests that
pMRI-FTB represents a promising noninvasive bio-
marker of tumor progression and clinical outcome,
which could prove to be useful in future clinical trials
and in the management of recurrent GBM.
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